Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Desoximetasone Cream USP (US RLD - Topicort Cream), 0.25%. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.
Desoximetasone is a strong corticosteroid, used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies and rash). It reduces the swelling, itching and redness that can occur in these types of conditions.
The group now has 219 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
